Survival after breast cancer is on the rise, thereby emphasizing the importance of discussions that focus on fertility and reproduction among younger survivors.
Survival after breast cancer is on the rise, thereby emphasizing the importance of these discussions that focus on fertility and reproduction among younger survivors. A recent study from Sweden, appearing in JAMA Oncology, investigated the long-term outcomes of fertility preservation among female survivor of breast cancer of reproductive age, finding they were more likely to have a live birth if they underwent FP and utilized assisted reproductive technology.
“Cryopreservation of oocytes and embryos after controlled ovarian stimulation is the standard strategy for fertility preservation (FP) in adult women. Until now, few studies have evaluated the long-term reproductive outcomes of FP in young women with BC,” the authors noted.
Their nationwide cohort study investigated the primary outcome of HRs for live births and assisted reproductive technology among 425 female breast cancers exposed to FP and 850 matched controls who were not, for a ratio of 1:2, respectively. The exposed group underwent FP at 1 of 7 Swedish university hospitals between January 1, 1994, and June 30, 2017.
The investigation found that more women in the exposed group had lower parity compared with the unexposed group: 71.1% vs 20.1%. These women were also younger, at a mean (SD) age of 32.1 (4.0) vs 33.3 (3.6) years for the unexposed group; had a higher rate of estrogen receptor-positive tumors, for 68.0% vs 60.6%; and had treatment schedules that included more chemotherapy treatments, at 93.9% vs 87.7%.
Additional analyses of the rate of live births among the exposed group resulted in higher numbers across the board compared with the unexposed controls:
Two measures were lower, however, but with positive implications: FP was linked to lower all-cause mortality (aHR, 0.4; 95% CI, 0.3-0.7) and 5-year cumulative incidence of death (5.3% [95% CI, 3.1%-9.0%] vs 11.1% [95% CI, 8.7%-14.1%]) in the exposed group.
Also in the exposed group, being nulliparous at diagnosis meant a 19% (95% CI, 14.2%-25.1%) 5-year cumulative incidence of live birth compared with 12.7% (95% CI, 7.6%-214.1%) seen in the exposed group. For those who had at least 1 child at diagnosis, the respective numbers were 20.2% (95% CI, 12.7%-31.3%) and 7.5% (95% CI, 5.3%-10.5%).
“Results of this nationwide cohort study indicate that although successful pregnancy after BC is possible both in women with and without FP, FP is associated with significantly higher rates of post-BC live births and use of [assisted reproductive technology] treatments, without any deleterious association with all-cause survival during a mean follow-up of 5.2 years,” the authors concluded. “These findings add to the current knowledge regarding FP treatments in women with BC.”
They believe their findings could enable oncologists and reproductive counselors to better initiate these conversations with their female patients who receive a breast cancer diagnosis.
Reference
Marklund A, Lundberg FE, Eloranta S, Hedayati E, Pettersson K, Rodriguez-Wallberg KA. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5957
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More